Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awdur:	Martin Sjöström (14845882) (author)
Awduron Eraill:	Shuang G. Zhao (12227671) (author), Samuel Levy (14960811) (author), Meng Zhang (14960814) (author), Yuhong Ning (279537) (author), Raunak Shrestha (14949693) (author), Arian Lundberg (14960817) (author), Cameron Herberts (14960820) (author), Adam Foye (14960823) (author), Rahul Aggarwal (14960826) (author), Junjie T. Hua (14960829) (author), Haolong Li (1532230) (author), Anna Bergamaschi (14960832) (author), Corinne Maurice-Dror (14960835) (author), Ashutosh Maheshwari (14960838) (author), Sujun Chen (3553841) (author), Sarah W.S. Ng (14960841) (author), Wenbin Ye (14960844) (author), Jessica Petricca (14960847) (author), Michael Fraser (522709) (author), Lisa Chesner (14960850) (author), Marc D. Perry (14960853) (author), Thaidy Moreno-Rodriguez (14960856) (author), William S. Chen (14960859) (author), Joshi J. Alumkal (14950518) (author), Jonathan Chou (14957015) (author), Alicia K. Morgans (5600567) (author), Tomasz M. Beer (14960862) (author), George V. Thomas (13187926) (author), Martin Gleave (146446) (author), Paul Lloyd (14960865) (author), Tierney Phillips (4664332) (author), Erin McCarthy (14960868) (author), Michael C. Haffner (14960871) (author), Amina Zoubeidi (14960874) (author), Matti Annala (219688) (author), Robert E. Reiter (14960877) (author), Matthew B. Rettig (14960880) (author), Owen N. Witte (14960883) (author), Lawrence Fong (14960886) (author), Rohit Bose (14960889) (author), Franklin W. Huang (10726678) (author), Jianhua Luo (14960892) (author), Anders Bjartell (199682) (author), Joshua M. Lang (12227674) (author), Nupam P. Mahajan (14960895) (author), Primo N. Lara (13009812) (author), Christopher P. Evans (14960898) (author), Phuoc T. Tran (14960901) (author), Edwin M. Posadas (14960904) (author), Chuan He (178952) (author), Xiao-Long Cui (2020402) (author), Jiaoti Huang (88989) (author), Wilbert Zwart (14960907) (author), Luke A. Gilbert (5513207) (author), Christopher A. Maher (14960910) (author), Paul C. Boutros (14954698) (author), Kim N. Chi (14960913) (author), Alan Ashworth (14957030) (author), Eric J. Small (14960916) (author), Housheng H. He (14960919) (author), Alexander W. Wyatt (14960922) (author), David A. Quigley (14957012) (author), Felix Y. Feng (14845891) (author)
Cyhoeddwyd:	2025
Pynciau:	Cancer Cancer Risk Factors Molecular and Cellular Biology Methods and Technology Epigenetics Epigenomics Genitourinary Cancers Prostate cancer Liquid Biopsy
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg

Figure 5 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Figure 3 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Figure 4 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Figure 6 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Figure 7 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
gan: Martin Sjöström (14845882)
Cyhoeddwyd: (2025)

Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
gan: Alex Chehrazi-Raffle (17079582)
Cyhoeddwyd: (2025)

Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
gan: Alex Chehrazi-Raffle (17079582)
Cyhoeddwyd: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
gan: Sofie H. Tolmeijer (15313251)
Cyhoeddwyd: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
gan: Sofie H. Tolmeijer (15313251)
Cyhoeddwyd: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
gan: Sofie H. Tolmeijer (15313251)
Cyhoeddwyd: (2025)

Supplementary Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations
gan: John Gallon (15096459)
Cyhoeddwyd: (2025)

Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
gan: Arian Lundberg (14960817)
Cyhoeddwyd: (2025)

Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
gan: Arian Lundberg (14960817)
Cyhoeddwyd: (2025)

Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
gan: Arian Lundberg (14960817)
Cyhoeddwyd: (2025)

Supplementary Table 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
gan: Arian Lundberg (14960817)
Cyhoeddwyd: (2025)

Supplementary Table 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
gan: Arian Lundberg (14960817)
Cyhoeddwyd: (2025)

Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
gan: Hong Qiu (14963144)
Cyhoeddwyd: (2025)

Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
gan: Hong Qiu (14963144)
Cyhoeddwyd: (2025)

Supplementary Table S1 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
gan: Rongxin Zhang (15293341)
Cyhoeddwyd: (2025)

Supplementary Table S2 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
gan: Rongxin Zhang (15293341)
Cyhoeddwyd: (2025)

Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
gan: Abdullah A. Osman (15056323)
Cyhoeddwyd: (2025)

Supplementary Figure S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
gan: Abdullah A. Osman (15056323)
Cyhoeddwyd: (2025)

Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
gan: Abdullah A. Osman (15056323)
Cyhoeddwyd: (2025)

Supplementary Table S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
gan: Abdullah A. Osman (15056323)
Cyhoeddwyd: (2025)

Supplementary Table S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
gan: Abdullah A. Osman (15056323)
Cyhoeddwyd: (2025)

Supplementary Table S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
gan: Abdullah A. Osman (15056323)
Cyhoeddwyd: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
gan: Emil Christensen (15054394)
Cyhoeddwyd: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
gan: Emil Christensen (15054394)
Cyhoeddwyd: (2025)

Supplementary Tables 1 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
gan: Prashant Chittiboina (15367044)
Cyhoeddwyd: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
gan: Stephanie Lheureux (16797697)
Cyhoeddwyd: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
gan: James R. Larkin (14936324)
Cyhoeddwyd: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
gan: Dipika R. Mohan (15011204)
Cyhoeddwyd: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
gan: Whitney L. Hensing (16461978)
Cyhoeddwyd: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
gan: Stephanie Lheureux (16797697)
Cyhoeddwyd: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
gan: Stephanie Lheureux (16797697)
Cyhoeddwyd: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
gan: Stephanie Lheureux (16797697)
Cyhoeddwyd: (2025)

Cannot write session to /tmp/vufind_sessions/sess_1od59k7tarm1sg98id4a21opup